Oncology Corporate Profile
This company does not have any pipeline products
5/16/2016 12:01 pm
(NASDAQ/Dow Jones Business News) May 16, 2016 - Valeant Pharmaceuticals International Inc. said Monday that it would expand discounts for a pair of its heart drugs following heavy scrutiny over its pricing tactics.
4/21/2016 10:05 am
(The Suncoast News [Tampa, FL]) Apr 20, 2016 - For cancer patients, it's getting harder to find access to quality, affordable care. More than 300 of the nation's cancer clinics have closed since 2008, and roughly 400 are struggling to make ends meet, according to the Community Oncology Alliance.
1/27/2016 11:05 am
(Yahoo! News/AFP) Jan 27, 2016 - Chronic infections, smoking and pollution have contributed to skyrocketing cases of cancer in China, with an estimated 4.3 million new diagnoses last year and 2.8 million deaths, researchers said Tuesday.
5/15/2015 12:01 pm
(Bloomberg) May 14, 2015 - A “safety switch” drug by Bellicum Pharmaceuticals Inc. killed off overactive immune system cells in a study of transplant patients, raising hopes that the treatment can also be used to manage risks in an experimental class of cancer therapies.
9/10/2014 06:05 am
(CNIO [Madrid, Spain]) Sept 9, 2014 - The experimental drug nintedanib, combined with standard chemotherapy with paclitaxel, causes a total remission of tumours in 50% of patients suffering from early HER-2-negative breast cancer, the most common type of breast cancer.
6/25/2014 06:03 am
(Bloomberg) June 25, 2014 - Basilea Pharmaceutica AG, a Swiss developer of an antibiotic to treat pneumonia, said the U.S. Food and Drug Administration asked for more data before approving the drug. The stock fell as much as 12 percent.
6/6/2014 07:00 am
(Wall Street Journal/Pharmalot blog) June 5, 2014 - For the past year, the pharmaceutical industry has been bracing for the Sunshine Act, a provision of health care reform that requires drug makers to gather and report payments and gifts to physicians.
6/2/2014 02:00 pm
(The Myeloma Beacon) June 2, 2014 - Panobinostat could be the next potential myeloma therapy approved by the U.S. Food and Drug Administration (FDA).
5/31/2014 12:04 pm
(AVEO Oncology) May 31, 2014 - AVEO Oncology today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy.
4/10/2014 11:05 am
(Genetic Engineering News) Apr 10, 2014 - Aveo Oncology and Biodesix said today they will co-develop Aveo’s ficlatuzumab with a Biodesix companion diagnostic already on the market, VeriStrat, to identify patients with advanced non-small cell lung cancer (NSCLC) who would be most likely to benefit from the hepatocyte growth factor (HGF) inhibitory antibody.
2/14/2014 10:01 am
(Reuters) Feb 14, 2014 - Aveo Oncology and Astellas Pharma Inc said they would end an agreement to develop Aveo's lead experimental drug that has seen a string of failures in multiple cancer indications.
1/30/2014 11:01 am
(Reuters) Jan 30, 2014 - Aveo Oncology said it would end a mid-stage trial testing its lead drug as a treatment for breast cancer, as the company did not have enough patients enrolled in the study.
1/30/2014 06:04 am
(MarketWatch) Jan 30, 2014 - AVEO Oncology today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment.
1/15/2014 11:03 am
(HealthLeaders Media) Jan 15, 2014 - The federal government has issued a new policy for public disclosure of physicians' Medicare payments.
1/15/2014 06:04 am
(MedPage Today) Jan 14, 2014 - Medicare will begin releasing payment data for individual physicians on a "case-by-case basis" as soon as this spring, the Centers for Medicare and Medicaid Services (CMS) announced Tuesday.
12/13/2013 03:01 pm
(Reuters) Dec 13, 2013 - Aveo Oncology said its lead experimental drug was unlikely to succeed in a mid-stage colon cancer study that was testing if the drug was superior to an approved treatment.
12/13/2013 07:01 am
(Yahoo! Finance) Dec 13, 2013 - AVEO Oncology today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.
7/25/2013 11:02 am
(Wall Street Journal) July 25, 2013 - The success of the new health-care law rides in large measure on whether young, healthy people like Gabe Meiffren, a cook at a Korean-Hawaiian food cart, decide to give up a chunk of disposable income to pay for insurance.
6/10/2013 07:02 am
(MarketWatch) June 10, 2013 - AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) informing the company that the FDA will not approve in its present form the New Drug Application (NDA) for AVEOâ€™s investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma (RCC).
6/6/2013 11:03 am
(TheStreet) June 6, 2013 - Aveo Oncology will succeed or fail depending on the potential for tivozanib to treat triple-negative breast cancer.
5/30/2013 11:03 am
(The Street) May 29, 2013 - The thrashing of Aveo Oncology's kidney cancer drug by an FDA advisory panel earlier this month will lead to "very significant consequences" at the struggling company, said Chairman Henri Termeer, in an interview following Aveo's annual shareholder meeting.
5/2/2013 05:01 pm
(Xconomy Boston) May 2, 2013 - A doomsday scenario played out for Aveo Oncology today. The Cambridge, MA-based company saw 13 of 14 members of an FDA advisory panel vote against its kidney cancer drug, tivozanib, saying it shouldn’t be cleared for sale in the U.S. because of questions about clinical trial design and the drug’s overall benefits to patients.
5/2/2013 12:04 pm
(BloombergBusinessweek) May 2, 2013 - Aveo Pharmaceuticals Inc. failed to win the backing of U.S. regulatory advisers for its lead product candidate, a kidney cancer drug, after the panelists questioned whether it was as effective as existing treatments.
4/30/2013 09:04 am
(Reuters) Apr 30, 2013 - Staff reviewers for the U.S. Food and Drug Administration have asked a panel of outside medical experts whether another clinical trial is needed before an experimental kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc can be approved.
4/25/2013 11:04 am
(The Street) Apr 25, 2013 - Next week is crucial for Aveo Oncology. On Tuesday, the FDA will post to its web site the agency's clinical review of Aveo's experimental kidney cancer drug tivozanib.